8-K current report · filed Aug 4, 2026

Revvity (RVTY) 8-K Current Report: August 4, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 2.02RVTY overview

Short answer

Revvity (RVTY) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Q2 fiscal 2026 results announced for quarter ended July 5, 2026.

Revvity 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 fiscal 2026 results announced for quarter ended July 5, 2026
  • Full financial results and management commentary available in Exhibit 99.1
  • Earnings release provides the basis for assessing quarterly performance and outlook

Item 8.01 · Other Events

  • Planned sale of substantially all China Immunodiagnostics assets for up to $200 million, subject to adjustments and closing conditions
  • Definitive agreement signed July 31, 2026, with closing expected by end of 2027
  • Pro forma financial statements reflect the anticipated divestiture’s impact on financial position and operations
  • Transaction execution and closing remain subject to risks, including required conditions and management’s expectations કામગીરી

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $730M, pro forma revenue $711M, with 3% organic growth and adjusted EPS $1.41 versus $1.18
  • Adjusted operating margin expanded to 28.9% from 26.6%, supported by $16M of tariff-related refunds
  • Diagnostics drove growth, with 11% organic revenue growth and margin expansion to 30.4% from 25.2%
  • China Immunodiagnostics divestiture removes approximately 6% of fiscal 2025 revenue, expected to close by end-2027
  • Full-year guidance raised to $2.83B-$2.86B revenue and $5.30-$5.40 pro forma adjusted EPS

Item EX-99.2 · Exhibit EX-99.2

  • China IDX divestiture removes $140M potential consideration from continuing operations, including transferred liabilities and excluding contingent consideration
  • Pro forma revenue reduction: $164.6M for FY2025, $42.8M for six months ended July 5, 2026
  • FY2025 pro forma operating income falls to $318.3M from $356.6M, reflecting a $38.3M disposition impact
  • FY2025 pro forma net income declines to $203.3M from $241.2M, with diluted EPS reduced to $1.74 from $2.07
  • Six-month 2026 pro forma net income rises to $101.9M from $92.5M, including a $42M probable-disposition loss in the comparative adjustment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Revvity 8-K filings

Get the next RVTY 8-K as it lands

Follow RVTY for push alerts, or ask the research agent what this filing means.